-
Media ReleaseNew Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
-
Media ReleaseFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
-
Media ReleaseNovartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
-
Media ReleaseNovartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network
-
Media ReleaseNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
-
Media ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
-
Media ReleaseNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
-
Media ReleaseLatest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
-
Media ReleaseNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
-
Media ReleaseNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
-
Media ReleaseNovartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
-
Media ReleaseNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors